ClinicalTrials.gg
CompletedNCT02629354Updated May 5, 2017Results posted

To Determine Blood Concentrations of Ibuprofen and Caffeine in a Tablet Against Ibuprofen Alone From Another Tablet

A Phase 1 interventional study of Ibuprofen and Caffeine in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in South Africa. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-05-05.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

The objective of the trial is to compare to combination of 400 mg ibuprofen and 100 mg caffeine against 400 mg ibuprofen alone under fed conditions

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy males and females, 18 to 50 years (inclusive) at time of screening.
  • (BMI) between 18.5 and 29.9 kg/m2 (inclusive).
  • Body mass not less than 50 kg.
  • Medical history, vital signs, physical examination, standard 12-lead (ECG) and laboratory investigations must be clinically acceptable or within laboratory reference ranges for the relevant laboratory tests, unless the PI considers the deviation to be irrelevant for the purpose of the study.
  • Non-smokers and mild or moderate smokers (\<= 10 cigarettes or pipes per day). Further inclusion criteria apply

Exclusion criteria

Exclusion criteria:

  • Evidence of psychiatric disorder, antagonistic personality, poor motivation, emotional or intellectual problems likely to limit the validity of consent to participate in the study or limit the ability to comply with protocol requirements.
  • Current alcohol use > 21 units of alcohol per week for males and > 14 units of alcohol per week for females. One unit is equal to beer [200 mL/10 ounces], wine [100 mL/4 ounces], or distilled spirits [25 mL/1 ounce]) per day
  • Regular exposure to substances of abuse (other than alcohol) within the past year.
  • Use of any medication, prescribed or over-the-counter or herbal remedies, within 2 weeks before the first administration of IMP except if this will not affect the outcome of the study in the opinion of the PI. In this study the concomitant use of hormonal is allowed.
  • Participation in another study with an experimental drug, where the last administration of the previous IMP was within 8 weeks (or within 5 elimination half-lives for chemical entities or 2 elimination half-lives for anti-bodies or insulin), whichever is the longer) before administration of IMP in this study, at the discretion of the PI.
  • Treatment within the previous 3 months before the first administration of IMP with any drug with a well-defined potential for adversely affecting a major organ or system.
  • History of or allergy (angioedema or urticaria) to the IMP or its or any related medication (Aspirin or any other NSAID).
  • Diagnosis of hypotension made during the screening period.
  • Diagnosis of hypertension made during the screening period or current diagnosis of hypertension.
  • Resting pulse of > 100 beats per minute or \< 40 beats per minute during the screening period, either supine or standing.
  • Renal impairment.
  • Positive urine screen for drugs of abuse. In case of a positive result the urine screen for drugs of abuse may be repeated once at the discretion of the PI.

Further exclusion criteria apply

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Ibuprofen and Caffeine

    Drug: Ibuprofen · Drug: Caffeine

  • Active comparator
    Ibuprofen

    Drug: Ibuprofen

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of S-ibuprofen

    This outcome measure presents the maximum observed concentration (Cmax) of S-ibuprofen in plasma obtained directly from the concentration-time data.

    Time frame: Within 2 hours prior to dosing and at 5, 10,15, 30 and 45 minutes and 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 5, 6, 8, 10, 12 and 24 hours post-dose

  2. Cmax of R-ibuprofen

    This outcome measure presents the Cmax of R-ibuprofen in plasma obtained directly from the concentration-time data.

    Time frame: Within 2 hours prior to dosing and at 5, 10,15, 30 and 45 minutes and 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 5, 6, 8, 10, 12 and 24 hours post-dose

  3. Cmax of Ibuprofen

    This outcome measure presents the Cmax of ibuprofen in plasma obtained directly from the concentration-time data.

    Time frame: Within 2 hours prior to dosing and at 5, 10,15, 30 and 45 minutes and 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 5, 6, 8, 10, 12 and 24 hours post-dose

  4. Area Under the Plasma Concentration of S-ibuprofen Versus Time Curve, From Time Zero to t (AUC0-t)

    This outcome measure presents the area under the plasma concentration of S-ibuprofen versus time curve, from time zero to t, where t is the time of the last quantifiable concentration (AUC0-t).

    Time frame: Within 2 hours prior to dosing and at 5, 10,15, 30 and 45 minutes and 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 5, 6, 8, 10, 12 and 24 hours post-dose

  5. AUC0-t of R-ibuprofen

    This outcome measure presents the area under the plasma concentration of R-ibuprofen versus time curve, from time zero to t, where t is the time of the last quantifiable concentration (AUC0-t).

    Time frame: Within 2 hours prior to dosing and at 5, 10,15, 30 and 45 minutes and 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 5, 6, 8, 10, 12 and 24 hours post-dose

  6. AUC0-t of Ibuprofen

    This outcome measure presents the area under the plasma concentration of ibuprofen versus time curve, from time zero to t, where t is the time of the last quantifiable concentration (AUC0-t).

    Time frame: Within 2 hours prior to dosing and at 5, 10,15, 30 and 45 minutes and 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 5, 6, 8, 10, 12 and 24 hours post-dose

Secondary outcomes

  1. Area Under the Plasma Concentration of S-ibuprofen Versus Time Curve, With Extrapolation to Infinity (AUC0-INF)

    This outcome measure presents the area under the plasma concentration of S-ibuprofen versus time curve, with extrapolation to infinity (AUC0-INF).

    Time frame: Within 2 hours prior to dosing and at 5, 10,15, 30 and 45 minutes and 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 5, 6, 8, 10, 12 and 24 hours post-dose

  2. AUC0-INF of R-ibuprofen

    This outcome measure presents the area under the plasma concentration of R-ibuprofen versus time curve, with extrapolation to infinity (AUC0-INF).

    Time frame: Within 2 hours prior to dosing and at 5, 10,15, 30 and 45 minutes and 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 5, 6, 8, 10, 12 and 24 hours post-dose

  3. AUC0-INF of Ibuprofen

    This outcome measure presents the area under the plasma concentration of ibuprofen versus time curve, with extrapolation to infinity (AUC0-INF).

    Time frame: Within 2 hours prior to dosing and at 5, 10,15, 30 and 45 minutes and 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 5, 6, 8, 10, 12 and 24 hours post-dose

07

Results

Posted Mar 16, 2017

Participant flow

Period 1
Participant flow — Period 1
MilestoneRef - TestTest - Ref
Started1818
Completed1818
Not completed00
Washout Period
Participant flow — Washout Period
MilestoneRef - TestTest - Ref
Started1818
Completed1818
Not completed00
Period 2
Participant flow — Period 2
MilestoneRef - TestTest - Ref
Started1818
Completed1818
Not completed00
Follow-up
Participant flow — Follow-up
MilestoneRef - TestTest - Ref
Started1818
Completed1818
Not completed00

Outcome measures

PrimaryMaximum Observed Plasma Concentration (Cmax) of S-ibuprofen

This outcome measure presents the maximum observed concentration (Cmax) of S-ibuprofen in plasma obtained directly from the concentration-time data.

Time frame:
Within 2 hours prior to dosing and at 5, 10,15, 30 and 45 minutes and 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 5, 6, 8, 10, 12 and 24 hours post-dose
Reported as:
Geometric mean · nanogram (ng)/ millilitre (mL)
Maximum Observed Plasma Concentration (Cmax) of S-ibuprofen
nanogram (ng)/ millilitre (mL)Reference ProductTest Product
Maximum Observed Plasma Concentration (Cmax) of S-ibuprofen13268.7 ± 38.014967.2 ± 34.9
Statistical analysis
  • Reference Product vs Test Product · ANOVA · Percent ratio test/ref: 113.77 · 90% CI 98.99 to 130.75Analysis of variance (ANOVA) with fixed effects for sequence, subject nested within sequence, period and product after logarithmic transformation of the data.
PrimaryCmax of R-ibuprofen

This outcome measure presents the Cmax of R-ibuprofen in plasma obtained directly from the concentration-time data.

Time frame:
Within 2 hours prior to dosing and at 5, 10,15, 30 and 45 minutes and 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 5, 6, 8, 10, 12 and 24 hours post-dose
Reported as:
Geometric mean · ng/mL
Cmax of R-ibuprofen
ng/mLReference ProductTest Product
Cmax of R-ibuprofen10495.7 ± 32.711454.6 ± 26.6
Statistical analysis
  • Reference Product vs Test Product · ANOVA · Percent ratio test/ref: 110.16 · 90% CI 96.32 to 125.97ANOVA with fixed effects for sequence, subject nested within sequence, period and product after logarithmic transformation of the data.
PrimaryCmax of Ibuprofen

This outcome measure presents the Cmax of ibuprofen in plasma obtained directly from the concentration-time data.

Time frame:
Within 2 hours prior to dosing and at 5, 10,15, 30 and 45 minutes and 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 5, 6, 8, 10, 12 and 24 hours post-dose
Reported as:
Geometric mean · ng/mL
Cmax of Ibuprofen
ng/mLReference ProductTest Product
Cmax of Ibuprofen23557.9 ± 34.826309.5 ± 30.3
Statistical analysis
  • Reference Product vs Test Product · ANOVA · Percent ratio test/ref: 112.69 · 90% CI 98.49 to 128.94ANOVA with fixed effects for sequence, subject nested within sequence, period and product after logarithmic transformation of the data.
PrimaryArea Under the Plasma Concentration of S-ibuprofen Versus Time Curve, From Time Zero to t (AUC0-t)

This outcome measure presents the area under the plasma concentration of S-ibuprofen versus time curve, from time zero to t, where t is the time of the last quantifiable concentration (AUC0-t).

Time frame:
Within 2 hours prior to dosing and at 5, 10,15, 30 and 45 minutes and 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 5, 6, 8, 10, 12 and 24 hours post-dose
Reported as:
Geometric mean · hour (h)*ng/mL
Area Under the Plasma Concentration of S-ibuprofen Versus Time Curve, From Time Zero to t (AUC0-t)
hour (h)*ng/mLReference ProductTest Product
Area Under the Plasma Concentration of S-ibuprofen Versus Time Curve, From Time Zero to t (AUC0-t)65110 ± 21.963150 ± 21.7
Statistical analysis
  • Reference Product vs Test Product · ANOVA · Percent ratio test/ref: 97.36 · 90% CI 94.61 to 100.19ANOVA with fixed effects for sequence, subject nested within sequence, period and product after logarithmic transformation of the data.
SecondaryArea Under the Plasma Concentration of S-ibuprofen Versus Time Curve, With Extrapolation to Infinity (AUC0-INF)

This outcome measure presents the area under the plasma concentration of S-ibuprofen versus time curve, with extrapolation to infinity (AUC0-INF).

Time frame:
Within 2 hours prior to dosing and at 5, 10,15, 30 and 45 minutes and 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 5, 6, 8, 10, 12 and 24 hours post-dose
Reported as:
Geometric mean · h*ng/mL
Area Under the Plasma Concentration of S-ibuprofen Versus Time Curve, With Extrapolation to Infinity (AUC0-INF)
h*ng/mLReference ProductTest Product
Area Under the Plasma Concentration of S-ibuprofen Versus Time Curve, With Extrapolation to Infinity (AUC0-INF)68900 ± 17.264990 ± 20.6
Statistical analysis
  • Reference Product vs Test Product · ANOVA · Percent ratio test/ref: 96.47 · 90% CI 93.74 to 99.28ANOVA with fixed effects for sequence, subject nested within sequence, period and product after logarithmic transformation of the data.
PrimaryAUC0-t of R-ibuprofen

This outcome measure presents the area under the plasma concentration of R-ibuprofen versus time curve, from time zero to t, where t is the time of the last quantifiable concentration (AUC0-t).

Time frame:
Within 2 hours prior to dosing and at 5, 10,15, 30 and 45 minutes and 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 5, 6, 8, 10, 12 and 24 hours post-dose
Reported as:
Geometric mean · h*ng/mL
AUC0-t of R-ibuprofen
h*ng/mLReference ProductTest Product
AUC0-t of R-ibuprofen42480 ± 19.041200 ± 15.9
Statistical analysis
  • Reference Product vs Test Product · ANOVA · Percent ratio test/ref: 97.55 · 90% CI 92.57 to 102.80ANOVA with fixed effects for sequence, subject nested within sequence, period and product after logarithmic transformation of the data.
PrimaryAUC0-t of Ibuprofen

This outcome measure presents the area under the plasma concentration of ibuprofen versus time curve, from time zero to t, where t is the time of the last quantifiable concentration (AUC0-t).

Time frame:
Within 2 hours prior to dosing and at 5, 10,15, 30 and 45 minutes and 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 5, 6, 8, 10, 12 and 24 hours post-dose
Reported as:
Geometric mean · h*ng/mL
AUC0-t of Ibuprofen
h*ng/mLReference ProductTest Product
AUC0-t of Ibuprofen108400 ± 18.4105300 ± 16.9
Statistical analysis
  • Reference Product vs Test Product · ANOVA · Percent ratio test/ref: 97.57 · 90% CI 94.50 to 100.73ANOVA with fixed effects for sequence, subject nested within sequence, period and product after logarithmic transformation of the data.
SecondaryAUC0-INF of R-ibuprofen

This outcome measure presents the area under the plasma concentration of R-ibuprofen versus time curve, with extrapolation to infinity (AUC0-INF).

Time frame:
Within 2 hours prior to dosing and at 5, 10,15, 30 and 45 minutes and 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 5, 6, 8, 10, 12 and 24 hours post-dose
Reported as:
Geometric mean · h*ng/mL
AUC0-INF of R-ibuprofen
h*ng/mLReference ProductTest Product
AUC0-INF of R-ibuprofen43910 ± 17.241960 ± 16.3
Statistical analysis
  • Reference Product vs Test Product · ANOVA · Percent ratio test/ref: 97.21 · 90% CI 92.22 to 102.46ANOVA with fixed effects for sequence, subject nested within sequence, period and product after logarithmic transformation of the data.
SecondaryAUC0-INF of Ibuprofen

This outcome measure presents the area under the plasma concentration of ibuprofen versus time curve, with extrapolation to infinity (AUC0-INF).

Time frame:
Within 2 hours prior to dosing and at 5, 10,15, 30 and 45 minutes and 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 5, 6, 8, 10, 12 and 24 hours post-dose
Reported as:
Geometric mean · h*ng/mL
AUC0-INF of Ibuprofen
h*ng/mLReference ProductTest Product
AUC0-INF of Ibuprofen113200 ± 14.6107300 ± 16.4
Statistical analysis
  • Reference Product vs Test Product · ANOVA · Percent ratio test/ref: 96.83 · 90% CI 93.75 to 100.01ANOVA with fixed effects for sequence, subject nested within sequence, period and product after logarithmic transformation of the data.

Adverse events

Collected over From first administration of study medication until 3 days after last dosing (up to 11 days).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Reference Product—0/36 (0%)0/36 (0%)
Test Product—0/36 (0%)0/36 (0%)

Baseline characteristics

Randomized population: all subjects randomized to a treatment sequence.

Age, Continuous
Age, Continuous(years)Ref - TestTest - RefTotal
Mean29.8 ± 8.4926.1 ± 5.5928.0 ± 7.33
Sex: Female, Male
Sex: Female, Male(Participants)Ref - TestTest - RefTotal
Female6511
Male121325
08

Study locations

1 site
  • Boehringer Ingelheim Investigational Site
    Bloemfontein, South Africa
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2015, a primary completion of Jan 2016 and a completion of Jan 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2017, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2015
First posted
Dec 14, 2015
Start
Nov 2015
Primary completionActual
Jan 2016
CompletionActual
Jan 2016
Results first posted
Mar 16, 2017
Last update
May 5, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02629354
Responsible party
Sponsor
First posted
Dec 14, 2015
Start date
Nov 2015
Primary completion
Jan 2016
Completion
Jan 2016
Results posted
Mar 16, 2017
Last update
May 5, 2017

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Caffeine

Start the discussion